Loxo takes center stage at ASCO with its groundbreaking shot at a biomarker-based cancer drug approval
CHICAGO — Loxo Oncology made it into the ASCO showcase over the weekend, boasting of a small but growing number of cases where children and adults with TRK fusion cancer responded to their lead drug, larotrectinib (LOXO-101). And they’re packaging it into a new drug application they expect to hustle to regulators either later this year or early 2018, while showing off a next-gen drug coming up the pipeline that they’re already claiming has established proof-of-concept evidence of efficacy in two cases.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.